Overactive Bladder and Urinary Incontinence

Overactive bladder (OAB) and incontinence are high-volume, quality-of-life diagnoses where APPs add enormous value. The 2024 AUA/SUFU idiopathic OAB guideline emphasizes shared decision-making, de-emphasizes a rigid step-wise sequence, and highlights the cognitive-risk conversation around antimuscarinics — a conversation Advanced Urology takes further than most.

5.1 Define the problem

OAB — urinary urgency — the sudden, compelling desire to void that is difficult to defer — usually with frequency and nocturia, with or without urgency incontinence, in the absence of infection or other identifiable pathology. It is a SYMPTOM syndrome and a diagnosis of exclusion. The underlying mechanism is detrusor overactivity: involuntary detrusor contractions during filling, driven by myogenic, neurogenic, and urothelial signaling abnormalities.

5.2 Work-up

• History: onset, triggers, urgency vs. stress, pad count and pad wetness, nocturia episodes, fluid/caffeine/alcohol intake, bowel habits, obstetric and surgical history, neurologic symptoms, and the medication list.

• A 3-day voiding diary is the single highest-yield, lowest-cost test in this space. It records times, voided volumes, leaks, and intake — and it frequently reveals that the problem is 3 liters of iced tea, not the bladder.

• Exam: abdominal and pelvic (atrophy, prolapse, cough stress test with a comfortably full bladder).

• Tests: urinalysis ± culture; post-void residual. Urodynamics is NOT routine for uncomplicated OAB — reserve it for neurogenic disease, prior anti-incontinence or pelvic surgery, suspected obstruction, a discordant story, or before invasive therapy (Chapter 25).

• Validated tools: OAB-q, ICIQ, or a simple urgency severity scale to quantify baseline and track response.

5.3 First-line: behavioral therapy

Behavioral therapy is not a throwaway recommendation — done properly it rivals medication, has no side effects, and is additive to everything else.

• Bladder training: scheduled/timed voiding on a fixed interval, gradually extending the interval by 15–30 minutes per week toward a 3–4 hour goal.

• Urge suppression technique: the counterintuitive one patients must be taught explicitly — when urgency hits, STOP and stand still (do not run to the bathroom, which raises intra-abdominal pressure and worsens leakage), perform several quick pelvic floor contractions to trigger the inhibitory reflex, breathe, let the urge wave pass, then walk calmly.

• Pelvic floor muscle training (Kegels): ideally taught by a pelvic floor physical therapist — a large proportion of patients contract the wrong muscles when self-taught.

• Fluid and dietary management: target roughly 6–8 cups/day (not more), reduce caffeine, alcohol, carbonation, and artificial sweeteners; stop fluids 2–3 hours before bed.

• Weight loss and constipation treatment: both produce measurable improvement in incontinence.

5.4 Pharmacologic therapy — beta-3 agonists preferred

Both drug classes carry Grade A evidence for efficacy, but Florida Urology Center strongly prefers a beta-3 agonist and uses anticholinergics (antimuscarinics) only very infrequently. We strongly advise against anticholinergics because of their side-effect burden — the association with dementia and cognitive impairment is real and dose-dependent, and they commonly cause constipation, dry mouth, blurred vision, urinary retention, confusion, and falls (especially in older adults). With an equally effective, better-tolerated alternative available, a beta-3 agonist is almost always the better choice.

5.5 Advanced therapies for refractory OAB

Patients who do not get adequate relief from behavioral therapy and a beta-3 agonist should be moved promptly to a definitive advanced therapy — and at our practice that often means we skip an indefinite medication trial entirely. These do not have to follow a rigid stepwise order and are chosen by patient preference.

Figure 5.1 — PNE. A temporary lead is placed through the S3 foramen and the wire exits the skin on the SAME side, connecting to an external stimulator worn for 3–7 days. A ≥ 50% improvement in the voiding diary is the threshold to proceed to implant.

Figure 5.2 — SNS / InterStim. The tined lead self-anchors at the S3 foramen and is tunneled subcutaneously to an implantable pulse generator (IPG) in the upper buttock. The lead and the generator sit on the SAME side — the system never crosses the midline.

5.6 Nocturia — treat the cause, not just the bladder

Waking to urinate is one of the most common and quality-of-life-limiting complaints, and it is frequently NOT a bladder problem — so resist reaching straight for a bladder drug. Nocturia is also independently associated with falls, fractures, and mortality in the elderly, so it deserves real attention.

• Sort the mechanism with a voiding diary — this is mandatory: (a) nocturnal polyuria (nighttime output > 33% of 24-hour output in older adults) — from evening fluids, caffeine/alcohol, CHF, peripheral edema, obstructive sleep apnea, or poorly timed diuretics; (b) reduced bladder capacity (OAB, BPH, incomplete emptying, IC); (c) global polyuria (> 40 mL/kg/24 h — diabetes mellitus or insipidus, primary polydipsia); or (d) a primary sleep disorder in which the patient wakes for another reason and then voids opportunistically.

• First steps: limit evening fluids/caffeine/alcohol; move diuretics to mid-afternoon; elevate the legs in the afternoon and use compression stockings for dependent edema; and screen for and treat obstructive sleep apnea — OSA is a hugely under-recognized cause and treating it can abolish the nocturia.

• Then target the cause: treat BPH or OAB when that is the driver. Consider desmopressin for true nocturnal polyuria in carefully selected patients — but monitor sodium closely (baseline, ~1 week, ~1 month, then periodically). Hyponatremia risk rises sharply with age; use the lowest dose and avoid in patients over ~65 with any risk factors, in CHF, or with baseline hyponatremia.

5.7 Stress urinary incontinence (SUI)

SUI is leakage with increased intra-abdominal pressure, from urethral hypermobility (loss of anatomic support) and/or intrinsic sphincter deficiency (a poorly coapting urethra). It is not treated with OAB medications.

• Diagnose it: a positive cough stress test with a comfortably full bladder is essentially confirmatory. Assess urethral mobility (Q-tip test) and look for prolapse.

• First-line: pelvic floor muscle training with a pelvic floor physical therapist; weight loss; treat chronic cough and constipation.

• Devices: incontinence pessary or urethral insert; vaginal support.

• In-office: Bulkamid urethral bulking — a hydrogel injected to improve urethral coaptation. Minimally invasive, repeatable, and a good option for women who want to avoid or are not candidates for a sling (Chapter 15).

• Surgical: midurethral sling (the most durable option for women).

• Magnetic pelvic floor therapy (“Magic Chair”): non-invasive, in-office electromagnetic stimulation to strengthen the pelvic floor — patients sit fully clothed; offered at our practice for stress and mixed incontinence.

• Post-prostatectomy male SUI: pelvic floor PT first (most improve over 6–12 months); then a male sling for mild-to-moderate leakage, the ProACT adjustable balloon system, or an artificial urinary sphincter — still the gold standard for severe leakage.